Harpoon Therapeutics

$19.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.98 (+5.35%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell HARP and other stocks, options, and ETFs commission-free!

About HARP

Harpoon Therapeutics, Inc. Common Stock, also called Harpoon Therapeutics, is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTACs) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. The listed name for HARP is Harpoon Therapeutics, Inc. Common Stock.

CEO
Gerald McMahon
Employees
61
Headquarters
South San Francisco, California
Founded
2015
Market Cap
607.55M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
243.26K
High Today
$19.48
Low Today
$17.80
Open Price
$18.44
Volume
196.79K
52 Week High
$25.24
52 Week Low
$10.27

HARP Earnings

-$0.65
-$0.43
-$0.22
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

FJUN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure